ATE451119T1 - Untereinheit-impfstoff gegen das respiratorische synzytialvirus - Google Patents

Untereinheit-impfstoff gegen das respiratorische synzytialvirus

Info

Publication number
ATE451119T1
ATE451119T1 AT04761567T AT04761567T ATE451119T1 AT E451119 T1 ATE451119 T1 AT E451119T1 AT 04761567 T AT04761567 T AT 04761567T AT 04761567 T AT04761567 T AT 04761567T AT E451119 T1 ATE451119 T1 AT E451119T1
Authority
AT
Austria
Prior art keywords
synzytial
subunity
virus
vaccine against
against respiratory
Prior art date
Application number
AT04761567T
Other languages
German (de)
English (en)
Inventor
Robert Anderson
Yan Huang
David Burt
Original Assignee
Id Biomedical Corp Quebec
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Id Biomedical Corp Quebec filed Critical Id Biomedical Corp Quebec
Application granted granted Critical
Publication of ATE451119T1 publication Critical patent/ATE451119T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AT04761567T 2003-07-15 2004-07-14 Untereinheit-impfstoff gegen das respiratorische synzytialvirus ATE451119T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US48780403P 2003-07-15 2003-07-15
US56758604P 2004-05-03 2004-05-03
US10/888,805 US7368537B2 (en) 2003-07-15 2004-07-09 Subunit vaccine against respiratory syncytial virus infection
PCT/CA2004/001007 WO2005007189A1 (en) 2003-07-15 2004-07-14 Subunit vaccine against respiratory syncytial virus infection

Publications (1)

Publication Number Publication Date
ATE451119T1 true ATE451119T1 (de) 2009-12-15

Family

ID=34084525

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04761567T ATE451119T1 (de) 2003-07-15 2004-07-14 Untereinheit-impfstoff gegen das respiratorische synzytialvirus

Country Status (9)

Country Link
US (2) US7368537B2 (enExample)
EP (2) EP1651264B1 (enExample)
JP (1) JP2007505033A (enExample)
AT (1) ATE451119T1 (enExample)
AU (1) AU2004257363A1 (enExample)
CA (1) CA2532164A1 (enExample)
DE (1) DE602004024542D1 (enExample)
ES (1) ES2337901T3 (enExample)
WO (1) WO2005007189A1 (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE489968T1 (de) * 2001-03-09 2010-12-15 Id Biomedical Corp Quebec Proteosom-liposaccharid-vakzine-adjuvans
US7255867B2 (en) * 2002-11-15 2007-08-14 Id Biomedical Corporation Of Quebec Vaccine
US7368537B2 (en) * 2003-07-15 2008-05-06 Id Biomedical Corporation Of Quebec Subunit vaccine against respiratory syncytial virus infection
ES2615169T3 (es) * 2003-10-22 2017-06-05 Id Biomedical Corporation Of Quebec Composiciones y procedimientos de activación de la inmunidad innata y alérgica
US20060229233A1 (en) * 2004-06-25 2006-10-12 Id Biomedical Corporation Compositions and methods for treating neurological disorders
KR101617895B1 (ko) 2007-12-24 2016-05-03 글락소스미스클라인 바이오로지칼즈 에스.에이. 재조합 ｒｓｖ 항원
US20110177117A1 (en) * 2008-07-18 2011-07-21 Normand Blais Chimeric respiratory syncytial virus polypeptide antigens
WO2010075491A2 (en) * 2008-12-24 2010-07-01 University Of Rochester Recombinant expression of self-folding neutralizing epitope-bearing subdomains of the respiratory syncytial virus attachment and fusion proteins
MX2011013566A (es) * 2009-06-19 2012-06-28 Eyegene Inc Vacunas para cancer cervical.
DK2445526T3 (en) 2009-06-24 2016-06-27 Glaxosmithkline Biologicals Sa Recombinant RSV antigens.
MX2012000036A (es) 2009-06-24 2012-02-28 Glaxosmithkline Biolog Sa Vacuna.
CA2803282C (en) 2009-07-06 2018-05-01 David E. Anderson Methods for preparing vesicles and formulations produced therefrom
CN102482666B (zh) 2009-07-06 2017-02-08 变异生物技术公司 制备囊泡的方法和由其产生的制剂
TW201116294A (en) 2009-07-15 2011-05-16 Novartis Ag RSV F protein compositions and methods for making same
CA2770304C (en) * 2009-08-04 2019-11-26 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, Centers For Disease Control And Prevention Anti-rsv immunogens and methods of immunization
WO2011030218A1 (en) 2009-09-10 2011-03-17 Novartis Ag Combination vaccines against respiratory tract diseases
US8730396B2 (en) * 2010-06-23 2014-05-20 MindTree Limited Capturing events of interest by spatio-temporal video analysis
SI2591114T1 (sl) * 2010-07-06 2016-10-28 Glaxosmithkline Biologicals S.A. Imunizacija velikih sesalcev z majhnimi odmerki RNA
ES2646669T3 (es) 2010-07-06 2017-12-14 Glaxosmithkline Biologicals Sa Procedimientos de aumento de una respuesta inmunitaria mediante el suministro de ARN
CN103096922B (zh) 2010-07-06 2019-08-06 变异生物技术公司 用于治疗流行性感冒的组合物和方法
AU2011276234B2 (en) 2010-07-06 2016-02-25 Glaxosmithkline Biologicals S.A. Liposomes with lipids having an advantageous pKa- value for RNA delivery
US11291635B2 (en) * 2010-07-06 2022-04-05 Glaxosmithkline Biological Sa Virion-like delivery particles for self-replicating RNA molecules
CA2799934C (en) 2010-07-07 2020-01-28 Artificial Cell Technologies, Inc. Respiratory syncytial virus antigenic compositions and methods
WO2012031043A1 (en) * 2010-08-31 2012-03-08 Novartis Ag Pegylated liposomes for delivery of immunogen-encoding rna
BR112013004879A2 (pt) * 2010-08-31 2018-04-24 Novartis Ag lipossomas pequenos para entrega de rna que codifica imunogénio
EP3520813B1 (en) 2010-10-11 2023-04-19 GlaxoSmithKline Biologicals S.A. Antigen delivery platforms
KR20120068647A (ko) * 2010-12-18 2012-06-27 아이진 주식회사 개선된 면역반응을 유도하는 백신
US20130323280A1 (en) * 2011-01-13 2013-12-05 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
BR112013017939B1 (pt) 2011-01-13 2022-11-16 Variation Biotechnologies Inc Composição imunogênica liofilizada termoestável, uso e método para preparação da mesma
RU2456020C1 (ru) * 2011-03-30 2012-07-20 Государственное образовательное учреждение дополнительного профессионального образования Российская медицинская академия последипломного образования Федерального агентства по здравоохранению и социальному развитию (ГОУ ДПО РМАПО Росздрава) Способ профилактики гриппа и острых респираторных инфекций у детей с бронхиальной астмой
EP2701734B1 (en) * 2011-04-26 2019-09-25 Molecular Express, Inc. Liposomal formulations
CN103842374A (zh) 2011-05-13 2014-06-04 诺华股份有限公司 融合前的rsv f抗原
EP3854413A1 (en) 2011-07-06 2021-07-28 GlaxoSmithKline Biologicals SA Immunogenic combination compositions and uses thereof
EP2802353A4 (en) 2012-01-12 2015-12-02 Variation Biotechnologies Inc COMPOSITIONS AND METHOD FOR THE TREATMENT OF VIRUS INFECTIONS
CN104244984B (zh) 2012-01-27 2020-03-31 变异生物技术公司 用于治疗剂的方法和组合物
EA201891945A3 (ru) 2012-08-01 2019-05-31 Бавариан Нордик А/С Вакцина рекомбинантного модифицированного вируса осповакцины анкара (mva) респираторно-синцитиального вируса (rsv)
SG11201500573RA (en) 2012-08-06 2015-02-27 Glaxosmithkline Biolog Sa Method for eliciting in infants an immune response against rsv and b. pertussis
US20140037680A1 (en) 2012-08-06 2014-02-06 Glaxosmithkline Biologicals, S.A. Novel method
AU2014304545A1 (en) 2013-08-05 2016-02-25 Glaxosmithkline Biologicals S.A. Combination immunogenic compositions
US9415101B2 (en) * 2013-09-25 2016-08-16 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
KR101695518B1 (ko) * 2014-09-30 2017-01-12 이화여자대학교 산학협력단 호흡기 신시치아 바이러스 범용 백신
JP7086000B2 (ja) 2015-11-10 2022-06-17 オハイオ・ステート・イノヴェーション・ファウンデーション 体液性親和性の加速に関する方法及び組成物
US11773143B2 (en) 2017-10-13 2023-10-03 Trellis Bioscience, Llc Conformational epitopes in respiratory syncytial virus G protein central conserved region
EP3833677A4 (en) 2018-08-08 2022-04-27 Trellis Bioscience, Inc. IMPROVED RSV PASSIVE AND ACTIVE VACCINES

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4707543A (en) * 1985-09-17 1987-11-17 The United States Of America As Represented By The Secretary Of The Army Process for the preparation of detoxified polysaccharide-outer membrane protein complexes, and their use as antibacterial vaccines
US5726292A (en) * 1987-06-23 1998-03-10 Lowell; George H. Immuno-potentiating systems for preparation of immunogenic materials
US5576016A (en) * 1993-05-18 1996-11-19 Pharmos Corporation Solid fat nanoemulsions as drug delivery vehicles
US5961970A (en) * 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
EP0854729B2 (en) * 1995-09-18 2008-10-22 United States Army Medical Research Materiel Command (USAMRMC) Improved methods for the production of non-covalently complexed and multivalent proteosome sub-unit vaccines
US5848152A (en) 1995-09-26 1998-12-08 Motorola, Inc. Communication device having interchangeable faceplates and active keypad cover
US6699478B1 (en) * 1997-09-19 2004-03-02 Wyeth Holdings Corporation Enhanced immune response to attachment (G) protein of Respiratory Syncytial Virus
BR9812240A (pt) * 1997-09-19 2000-07-18 American Cyanamid Co Proteìna g alterada ou polipeptìdeo do rsv, uso da mesma, molécula de ácido nucleico codificando uma proteìna g alterada ou um polipeptìdeo do rsv, construção do ácido nucleico, célula hospedeira recombinante, processos de produção de uma proteìna g alterada ou polipeptìdeo do rsv composição imunogênica, de indução de uma resposta imune em um vertebrado, de inibir a indução do aumento da doença após a vacinação e subsequente infecção de um vertebrado com o rsv e de imunização de um vertebrado contra o rsv, composição de vacina, vacina, e, composição imunogênica
IL150602A0 (en) 2000-02-15 2003-02-12 Id Biomedical Corp Quebec Proteosome influenza vaccine
FR2819810B1 (fr) 2001-01-23 2004-05-28 Pf Medicament Peptides non glycosyles derives de la proteine g du vrs et leur utilisation dans un vaccin
ATE489968T1 (de) * 2001-03-09 2010-12-15 Id Biomedical Corp Quebec Proteosom-liposaccharid-vakzine-adjuvans
US7368537B2 (en) * 2003-07-15 2008-05-06 Id Biomedical Corporation Of Quebec Subunit vaccine against respiratory syncytial virus infection

Also Published As

Publication number Publication date
WO2005007189A1 (en) 2005-01-27
EP1651264B1 (en) 2009-12-09
CA2532164A1 (en) 2005-01-27
US7368537B2 (en) 2008-05-06
US20080226673A1 (en) 2008-09-18
EP1651264A1 (en) 2006-05-03
EP2204188A1 (en) 2010-07-07
ES2337901T3 (es) 2010-04-30
JP2007505033A (ja) 2007-03-08
US20050042230A1 (en) 2005-02-24
AU2004257363A1 (en) 2005-01-27
DE602004024542D1 (de) 2010-01-21

Similar Documents

Publication Publication Date Title
DE602004024542D1 (de) Untereinheit-impfstoff gegen das respiratorische synzytialvirus
ATE426412T1 (de) Adjuvante influenza-vakzine
WO2006068663A3 (en) Vaccine compositions for treating coronavirus infection
WO2004060308A3 (en) Thiosemicarbazones as anti-virals and immunopotentiators
CY2013026I1 (el) Πολυπεπτιδιου-εμβολια για ευρεια προστασια εναντι υπερ-λοιμογονων μηνιγγιοκοκκικων γενεαλογικων σειρων
CY2016018I1 (el) Εμβολιο κατα του ιου του δυτικου νειλου
DK1409692T3 (da) Nye peptider afledt af G-proteinet fra RSV, og anvendelse heraf i en vaccine
ATE553775T1 (de) Impstoffzusammesetzung
ATE485056T1 (de) Verbesserte impfstoffe
WO2004030608A3 (en) Nanoemulsion vaccines
DE60328481D1 (de) Schleimhautapplizierter impfstoff, der das adjuvanz chitosan und menigokokkenantigene enthält
CY1107146T1 (el) Μεθοδοι για προληψη και θεραπεια ασθενειας alzheimer (ad)
EP1307130A4 (en) VACCINE AGAINST THE VIRUS OF HUMAN IMMUNODEFICIENCY
DK1427444T3 (da) West-nil-vaccine
ATE452900T1 (de) Impfstoff gegen das west-nile-virus
EP1423141A4 (en) VACCINE
NO20033882D0 (no) Vaksine
NO20052149D0 (no) Vaksine.
DE60130998D1 (de) Ribavirin-enthaltende vakzine
ATE269104T1 (de) Salmonella impfstoff, der keinen antikörper gegen flagellin oder gegen flagella induziert
WO2004091524A3 (en) Respiratory virus vaccines
ATE518012T1 (de) Isolate des das reproduktions- und atemwegssyndrom verursachenden schweinevirus und ihre verwendung
ATE380557T1 (de) E. coli vakzin zur protektion von geflügel gegen colibazillose
ATE392903T1 (de) Impfstoff gegen pferdeherpesvirus
EA200301151A1 (ru) Вакцина против натуральной оспы

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties